Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Toyo Jozo was a significant Japanese pharmaceutical and fermentation specialist that operated as a core member of the Asahi Kasei Group until its full merger into Asahi Kasei in 1992. Originally established in 1920 as a manufacturer of alcoholic beverages, the company successfully pivoted to life sciences by leveraging its advanced fermentation technology to produce penicillin and other antibiotics. Its most notable contribution to medicine was the discovery and development of Bredinin (mizoribine), an immunosuppressant widely used in renal transplantation and the treatment of lupus nephritis and rheumatoid arthritis. Beyond therapeutics, Toyo Jozo was a leader in the production of diagnostic enzymes and food additives. Today, its pharmaceutical legacy and research facilities form the foundation of Asahi Kasei Pharma's operations.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Toyo Jozo.